Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome

被引:2
|
作者
Liu, Chia-Chu [1 ,2 ,3 ,4 ]
Huang, Shu-Pin [1 ,2 ]
Lee, Yung-Chin [1 ,2 ,5 ]
Lee, Cheng-Hsueh [1 ]
Huang, Tsung-Yi [1 ]
Geng, Jiun-Hung [2 ,5 ]
Chang, Che-Wei [1 ,3 ]
Lin, Chung-Yu [1 ]
Juan, Yung-Shun [1 ,2 ]
Wu, Wen-Jeng [1 ,2 ]
Hsieh, Tusty-Jiuan [4 ,6 ]
机构
[1] Kaohsiung Med Univ, Dept Urol, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Urol, Kaohsiung, Taiwan
[3] Pingtung Hosp, Dept Urol, Minist Hlth & Welf, Pingtung, Taiwan
[4] Kaohsiung Med Univ, Res Ctr Precis Environm Med, Kaohsiung, Taiwan
[5] Kaohsiung Municipal Siaogang Hosp, Dept Urol, Kaohsiung, Taiwan
[6] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
metabolic dysfunction-associated fatty liver disease; testosterone deficiency; aging men; metabolic syndrome; insulin resistance; ANDROGEN DEFICIENCY; RISK; PREVALENCE;
D O I
10.3389/fendo.2023.1252774
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a valuable marker for identifying individuals at increased risk of metabolic dysfunction, liver-related complications, and cardiovascular disease. However, the association between MAFLD and testosterone deficiency (TD) in aging men remains poorly understood. This study aimed to investigate the association between MAFLD and the risk of TD in aging Taiwanese men, with a specific focus on those without metabolic syndrome (MetS).Methods: A free health screening program was conducted for Taiwanese men aged over 40 years in Kaohsiung, Taiwan. Participants underwent physical examinations, completed questionnaires regarding demographics, medical history, and clinical symptoms of TD, and provided 20-mL whole blood samples for biochemical, adipocytokine, and hormonal evaluations. Fatty liver index was used to evaluate the risk of fatty liver. Diagnostic criteria for MAFLD included fatty liver along with overweight/obesity, type 2 diabetes, or evidence of metabolic dysregulation.Results: A total of 631 men (mean age: 54.4 +/- 8.4 years) were enrolled. The prevalence rates of TD and MetS were significantly higher in men with MAFLD compared to those without (both p < 0.001). Additionally, the presence of MAFLD showed a significant correlation with adipocytokines associated with insulin resistance, such as adiponectin, leptin, and retinol-binding protein-4 (RBP-4) levels (all p < 0.001). Among men without MetS, those with MAFLD had a 3.89- and 4.74-fold higher risk of total testosterone < 300 ng/dL and TD, respectively, after adjusting for potential covariates.Conclusion: MAFLD is associated with an elevated risk of TD in aging Taiwanese men, particularly in the absence of MetS. This finding suggests that MAFLD could serve as an early predictor of TD, facilitating the identification of high-risk individuals and enabling timely interventions. Further research is needed to validate these findings and explore the underlying mechanisms linking MAFLD, TD, and MetS in diverse populations.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Fatty liver index is associated with the risk of testosterone deficiency in aging men without metabolic syndrome
    Liu, Chia-Chu
    Huang, Shu-Pin
    Hsieh, Tusty-Jiuan
    Lee, Cheng-Hsueh
    Cheng, Kai-Hung
    Huang, Tsung-Yi
    Geng, Jiun-Hung
    Li, Ching-Chia
    Wu, Wen-Jeng
    Lee, Yung-Chin
    ANDROLOGY, 2021, 9 (03) : 863 - 872
  • [2] Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
    Lim, Soo
    Kim, Jin-Wook
    Targher, Giovanni
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2021, 32 (07): : 500 - 514
  • [3] Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Kani, Haluk Tarik
    Demirtas, Coskun Ozer
    Keklikkiran, Caglayan
    Ergenc, Ilkay
    Mehdiyev, Shahin
    Akdeniz, Esra
    Yilmaz, Yusuf
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2021, 32 (08): : 661 - 666
  • [4] The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
    Barrera, Francisco
    Uribe, Javier
    Olvares, Nixa
    Huerta, Paula
    Cabrera, Daniel
    Romero-Gomez, Manuel
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [5] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [6] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Michel, Maurice
    Labenz, Christian
    Armandi, Angelo
    Kaps, Leonard
    Kremer, Wolfgang Maximilian
    Galle, Peter R.
    Grimm, Daniel
    Sprinzl, Martin
    Schattenberg, Joern M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
    Wang, Xiaolin
    Xie, Qing
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (01) : 128 - 133
  • [8] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [9] Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease
    Perdomo, Carolina M.
    Nunez-Cordoba, Jorge M.
    Ezponda, Ana
    Mendoza, Francisco J.
    Ampuero, Javier
    Bastarrika, Gorka
    Fruhbeck, Gema
    Escalada, Javier
    FRONTIERS IN MEDICINE, 2022, 9
  • [10] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Wang, Ting-Yao
    Wang, Rui-Fang
    Bu, Zhi-Ying
    Targher, Giovanni
    Byrne, Christopher D.
    Sun, Dan-Qin
    Zheng, Ming-Hua
    NATURE REVIEWS NEPHROLOGY, 2022, 18 (04) : 259 - 268